Table 4.

Overall number and annual rate of recurrences according to treatment and level of estrogen module (split at the median) in all patients and in the HER2 subgroup

HER2HER2
YearsAllHER2Low Estrogen-moduleHigh Estrogen-module
0–5AllNo. of recurrences100774730
Recurrence/y1.82%1.56%2.06%1.14%
AnastrozoleNo. of recurrences41311714
Recurrence/y1.50%1.26%1.52%1.04%
TamoxifenNo. of recurrences59463016
Recurrence/y2.02%1.88%2.58%1.24%
5–10AllNo. of recurrences1151044559
Recurrence/y2.60%2.60%2.46%2.72%
AnastrozoleNo. of recurrences62592237
Recurrence/y2.80%2.94%2.48%3.34%
TamoxifenNo. of recurrences53452322
Recurrence/y2.40%2.26%2.50%2.06%

NOTE: Overall number and annual rate of recurrences according to treatment and HER2 status. Data are compared with that with patients in the main ATAC trial not receiving chemotherapy and those from the UK not receiving chemotherapy.